|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001779,
umls-concept:C0006684,
umls-concept:C0021467,
umls-concept:C0021469,
umls-concept:C0022661,
umls-concept:C0030705,
umls-concept:C0034634,
umls-concept:C0160420,
umls-concept:C0403447,
umls-concept:C0441766,
umls-concept:C0910022,
umls-concept:C1366622,
umls-concept:C1522496,
umls-concept:C1549649,
umls-concept:C2349209
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2011-6-10
|
|
pubmed:abstractText |
There is a growing body of evidence that advanced glycation end products (AGE) and their receptor (RAGE) system are implicated in chronic kidney disease (CKD). We have previously found that a long-acting calcium channel blocker, azelnidipine, but not amlodipine, improves renal injury in CKD patients. However, little is known about the effect of azelnidipine on the AGE-RAGE axis in humans. In this study, we examined whether azelnidipine addition could have renoprotective properties in hypertensive CKD patients by reducing serum levels of AGE and soluble form of RAGE (sRAGE). Thirty nondiabetic stage I or II CKD patients who had already been treated with angiotensin II receptor blockers were enrolled in this study.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amlodipine,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II Type 1 Receptor...,
http://linkedlifedata.com/resource/pubmed/chemical/Antihypertensive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Azetidinecarboxylic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium Channel Blockers,
http://linkedlifedata.com/resource/pubmed/chemical/Dihydropyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Glycosylation End Products, Advanced,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/advanced glycosylation end-product...,
http://linkedlifedata.com/resource/pubmed/chemical/azelnidipine
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1932-8737
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
© 2011 Wiley Periodicals, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
34
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
372-7
|
|
pubmed:meshHeading |
pubmed-meshheading:21432860-Adult,
pubmed-meshheading:21432860-Amlodipine,
pubmed-meshheading:21432860-Analysis of Variance,
pubmed-meshheading:21432860-Angiotensin II Type 1 Receptor Blockers,
pubmed-meshheading:21432860-Antihypertensive Agents,
pubmed-meshheading:21432860-Azetidinecarboxylic Acid,
pubmed-meshheading:21432860-Calcium Channel Blockers,
pubmed-meshheading:21432860-Chronic Disease,
pubmed-meshheading:21432860-Dihydropyridines,
pubmed-meshheading:21432860-Female,
pubmed-meshheading:21432860-Glycosylation End Products, Advanced,
pubmed-meshheading:21432860-Humans,
pubmed-meshheading:21432860-Hypertension,
pubmed-meshheading:21432860-Japan,
pubmed-meshheading:21432860-Kidney,
pubmed-meshheading:21432860-Kidney Diseases,
pubmed-meshheading:21432860-Male,
pubmed-meshheading:21432860-Middle Aged,
pubmed-meshheading:21432860-Proteinuria,
pubmed-meshheading:21432860-Receptors, Immunologic,
pubmed-meshheading:21432860-Time Factors,
pubmed-meshheading:21432860-Treatment Outcome
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease.
|
|
pubmed:affiliation |
Division of Nephrology, Department of Internal Medicine, Shinmatsudo Central General Hospital, Matsudo, Japan.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
